Home » Members » Our Members » Mater Research
Mater Research
www.materresearch.org.au
Mater Research is a world class institute that is committed to academic medicine and aims to discover, develop, translate, and commercialise medical research that integrates with relevant areas of excellence within clinical practice. Proud of its strong history and relationship with Mater Group, Mater Research is continuing to drive medical innovation which can be translated into clinical care for the benefit of all.
Principal research areas
- Cancer biology
- Disease prevention
- Immunity, infection & inflammation
- Metabolic & cardiovascular disease
- Biological therapies
- Musculo-skeletal & neural therapies
- Maternal & newborn health
- Growth & development
- Child & adolescent psychology
Professor Maher Gandhi
Subscribe to AAMRI's e-news
- Skip to content
- Queensland’s research capability
- Queensland science capability directory
Mater Research
Mercy Partners
Share this page
Back to directory
Mater Research is a world class medical research institute based at South Brisbane. Our bench to bedside philosophy means we work across Mater Health’s hospitals and health services, and the world-class Translational Research Institute (TRI). We work closely with Mater Health and Mater Education to turn scientific discovery into the best possible treatment, care, and outcomes for patients and our broader community. With expertise across all facets of medical research (study design, ethics and governance, data collection, biobank management, analysis, and implementation science) we are responsible for robust management of all research and clinical trials at Mater. We also maintain a broad external focus, horizon scanning national and international high quality research to reduce duplication of effort and wasted resources.
- Research hospital
- Not-for-profit
Strengths and capabilities
- Mothers’, babies’ and women’s health
- Cancer biology and care
- Neurosciences and cognitive health
- Chronic disease biology and care
- Optimising acute care
Facilities and major equipment
- PC2 Laboratories
- PCR Analysis Unit
- Genomic Analysis Unit
- Metabolic Analysis Unit
- Respiratory Biobank
- Micromanipulator - Single Cell Isolation
Lead researchers
- Associate Professor Ingrid Winkler —Her team identified a molecule that regulates stem cell function, which may make chemotherapy safer. Findings published in Nature Medicine.
- Professor John Hooper —Over 70 scientific publications of research focused upon understanding the molecular mechanisms underlying cancer.
- Professor Geoffrey Faulkner —Published over 60 peer-reviewed articles ( (>13,000 citations, h-index 34) mostly in top-tier journals and grant funding over $34M
Achievements of the centre
- Mater researcher led an international study of stillbirth rates in high-income countries, findings published in The Lancet
- Research findings published in Nature Medicine identify a molecule that regulates stem cell function, which may make chemotherapy safer
- Mater Researchers feature in ‘Ten of the best’ for their outstanding research in NHMRC both in 2015 and 2014
- Project lead of the Queensland Family Cohort Study
Other centre in Queensland
- Centre of Research Excellence in Stillbirth
Key science sectors
More information about the sectors this centre is involved in:
- Health and medical
- Social sciences
Update details
Is this your centre? See any issues? Send a request to update your listing .
Page feedback
Website feedback
Please share your experience with this website’s content and functionality . For all other enquiries, comments and complaints , please contact us .
- Strongly agree
- Strongly disagree
- Your comments about this page’s content or functionality (required)
- Contact Please provide your email address or phone number if you are happy for us to contact you with any follow-up questions.
The department collects personal information from you, including information about your email address and telephone number.
We collect this information to contact you with any follow-up questions. We will only use your information for this purpose. It will otherwise not be used or disclosed unless authorised or required by law. Your personal information will be handled in accordance with the Information Privacy Act 2009 .
We've detected unusual activity from your computer network
To continue, please click the box below to let us know you're not a robot.
Why did this happen?
Please make sure your browser supports JavaScript and cookies and that you are not blocking them from loading. For more information you can review our Terms of Service and Cookie Policy .
For inquiries related to this message please contact our support team and provide the reference ID below.
Biomimetic UHMWPE/HA scaffolds with rhBMP-2 and erythropoietin for reconstructive surgery
Affiliations.
- 1 National University of Science and Technology "MISIS", Leninskiy pr. 4, 119049 Moscow, Russia; N. F. Gamaleya National Research Center of Epidemiology and Microbiology, Ministry of Health of the Russian Federation, Gamaleya Str. 18, 123098 Moscow, Russia. Electronic address: [email protected].
- 2 National University of Science and Technology "MISIS", Leninskiy pr. 4, 119049 Moscow, Russia.
- 3 N. F. Gamaleya National Research Center of Epidemiology and Microbiology, Ministry of Health of the Russian Federation, Gamaleya Str. 18, 123098 Moscow, Russia.
- 4 N. F. Gamaleya National Research Center of Epidemiology and Microbiology, Ministry of Health of the Russian Federation, Gamaleya Str. 18, 123098 Moscow, Russia; Belozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, 119992 Moscow, Russia.
- 5 National University of Science and Technology "MISIS", Leninskiy pr. 4, 119049 Moscow, Russia; N. N. Blokhin National Medical Research Centre of Oncology of the Health Ministry of Russia, Kashirskoye sh. 24, 115478 Moscow, Russia.
- 6 TU Dortmund University "TUD", Department of Materials Test Engineering (WPT), Baroper Str. 303, 44227 Dortmund, Germany.
- 7 N. F. Gamaleya National Research Center of Epidemiology and Microbiology, Ministry of Health of the Russian Federation, Gamaleya Str. 18, 123098 Moscow, Russia; All-Russia Research Institute of Agricultural Biotechnology, Timiryazevskaya Str. 42, 127550 Moscow, Russia.
- 8 N. F. Gamaleya National Research Center of Epidemiology and Microbiology, Ministry of Health of the Russian Federation, Gamaleya Str. 18, 123098 Moscow, Russia; Belozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, 119992 Moscow, Russia; All-Russia Research Institute of Agricultural Biotechnology, Timiryazevskaya Str. 42, 127550 Moscow, Russia.
- PMID: 32279822
- DOI: 10.1016/j.msec.2020.110750
A promising direction for the replacement of expanded bone defects is the development of bioimplants based on synthetic biocompatible materials impregnated with growth factors that stimulate bone remodeling. Novel biomimetic highly porous ultra-high molecular weight polyethylene (UHMWPE)/40% hydroxyapatite (HA) scaffold for reconstructive surgery with the porosity of 85 ± 1% vol. and a diameter of pores in the range of 50-800 μm was developed. The manufacturing process allowed the formation of trabecular-like architecture without additional solvents and thermo-oxidative degradation. Biomimetic UHMWPE/HA scaffold was biocompatible and provided effective tissue ingrowth on a model of critical-sized cranial defects in mice. The combined use of UHMWPE/HA with Bone Morphogenetic Protein-2 (BMP-2) demonstrated intensive mineralized bone formation as early as 3 weeks after surgery. The addition of erythropoietin (EPO) significantly enhanced angiogenesis in newly formed tissues. The effect of EPO of bacterial origin on bone tissue defect healing was demonstrated for the first time. The developed biomimetic highly porous UHMWPE/HA scaffold can be used separately or in combination with rhBMP-2 and EPO for reconstructive surgery to solve the problems associated with difference between implant architecture and trabecular bone, low osteointegration and bioinertness.
Keywords: Hydroxyapatite; Microstructure; Protein; Scaffold; UHMWPE.
Copyright © 2020 Elsevier B.V. All rights reserved.
- Biocompatible Materials / chemistry*
- Biocompatible Materials / pharmacology
- Bone Diseases / surgery*
- Bone Diseases / therapy
- Bone Morphogenetic Protein 2 / chemistry*
- Bone Morphogenetic Protein 2 / metabolism
- Bone Morphogenetic Protein 2 / pharmacology
- Bone Morphogenetic Protein 2 / therapeutic use
- Bone Regeneration / drug effects
- Bone and Bones / pathology
- Bone and Bones / physiology
- Drug Carriers / chemistry
- Durapatite / chemistry*
- Erythropoietin / chemistry*
- Erythropoietin / metabolism
- Erythropoietin / pharmacology
- Mice, Inbred C57BL
- Mice, Inbred ICR
- Nanocomposites / chemistry
- Neovascularization, Physiologic / drug effects
- Plastic Surgery Procedures
- Polyethylenes / chemistry*
- Recombinant Proteins / chemistry
- Recombinant Proteins / metabolism
- Recombinant Proteins / pharmacology
- Recombinant Proteins / therapeutic use
- Transforming Growth Factor beta / chemistry*
- Transforming Growth Factor beta / metabolism
- Transforming Growth Factor beta / pharmacology
- Transforming Growth Factor beta / therapeutic use
- Biocompatible Materials
- Bone Morphogenetic Protein 2
- Drug Carriers
- Polyethylenes
- Recombinant Proteins
- Transforming Growth Factor beta
- recombinant human bone morphogenetic protein-2
- ultra-high molecular weight polyethylene
- Erythropoietin
IMAGES
VIDEO
COMMENTS
Key pancreatic protein linked to regulation of insulin production. Published in Nature Communications, Mater Researchers are one step closer to advancing diabetes treatment thanks to new research focusing on IL-22RA1—a protein receptor. Learn more.
History. Establishing a medical research institute at Mater was a long-term goal of the Sisters of Mercy and the Mater Health Services Governing Board. This desire and commitment culminated in July 1998 with the formation of the Mater Medical Research Institute, a development funded by the Sisters of Mercy and their supporters.
15 April 2014. Mater Research is a world class institute that is committed to academic medicine and aims to discover, develop, translate, and commercialise medical research that integrates with relevant areas of excellence within clinical practice. Proud of its strong history and relationship with Mater Group, Mater Research is continuing to ...
I had the honor to lead a unique institution that has absorbed the richest traditions of Russian medicine. National Medical Research Radiological Centre (NMRRC) united the best schools in surgery, radiology and urology, which were created by our great teachers - Peter Alexandrovich Hertsen, Anatoly Fedorovich Tsyba and Nikolai Alexandrovich Lopatkin.
With expertise across all facets of medical research (study design, ethics and governance, data collection, biobank management, analysis, and implementation science) we are responsible for robust management of all research and clinical trials at Mater. We also maintain a broad external focus, horizon scanning national and international high ...
Mater Medical Research Institute Limited was founded in 1906. The company's line of business includes providing noncommercial research. ...
ACTRN, ACTRN12619000037101 . Registered on 14 January 2019. Trial Sponsor: Mater Misericordiae Limited (MML) and Mater Medical Research Institute Limited (MMRI)-Raymond Terrace, South Brisbane, Brisbane, QLD, Australia.
We are Mater. As a Catholic not-for-profit ministry of Mercy Partners, Mater brings together our collective expertise and resources across health, education and research to help you make better choices about your health, every day. Through our extensive network of hospitals, health centres and related businesses, a nationally accredited ...
P. Hertsen Moscow Oncology Research Institute (MORI) - the branch of the FSBI "National Medical Research Radiological Centre" (NMRRC) of the Ministry of Health of the Russian Federation is the first oncological hospital in Russia with high-tech equipment, the latest ways and methods of diagnostics and treatment of tumors.
12/Jan/2022 Mater Group Research. Mater Research Executive Director Professor Maher Gandhi says a $2.8 million grant awarded to his team by the Medical Research Future Fund (MRFF) provides an exciting opportunity to trial a new immunotherapy to treat a rare but devastating blood cancer. The ground-breaking Australasian Leukaemia Lymphoma Group ...
Mater Medical Research Institute Limited Brisbane, Australia -Brisbane, Australia Education 2015 - 2016. 2013 - 2016. 2011 - 2012. 2007 - 2011. View Yuanhao's full profile See who you know in common Get introduced Contact Yuanhao directly Join to view full profile ...
Mater is a leader in healthcare, providing comprehensive care to meet the needs of the community. They offer a network of hospitals, health centers, a medical research institute, and pathology and pharmacy businesses. Mater is committed to its mission ... - https://mater.org.au
Research Programs. Mater Research is focused on improving health across all of life's stages from mother and baby health to healthcare delivery and innovation, cancer, neuroscience and chronic and integrated care. ... four are co-led by a clinical and biomedical lead while our Healthcare Delivery and Innovation Program has a medical and nursing ...
1 Department of Pediatric Surgery, Moscow Regional Scientific Research Clinical Institute M.F. Vladimirsky, Moscow, Russia; Department of Pediatric Neurosurgery, Russian Children's Clinical Hospital, Pirogov Russian National Research Medical University, Moscow, Russia. Electronic address: [email protected].
Peter TIMASHEV, Research Director | Cited by 4,995 | of I.M. Sechenov First Moscow State Medical University, Moscow | Read 372 publications | Contact Peter TIMASHEV
Mater Research is a recognised leader in innovative and impactful medical research delivering on Mater's mission to meet the unmet needs of Queenslanders, through a bench-to-bedside philosophy. ... forming the Mater Research Institute - The University of Queensland (MRI-UQ) alliance in 2013, bringing with it, strategic benefits for all ...
Affiliations 1 Laboratory of Angiopathology, Institute of General Pathology and Pathophysiology, 125315 Moscow, Russian Federation.; 2 Institute for Atherosclerosis Research, Skolkovo Innovative Center, 121609 Moscow, Russian Federation.; 3 Department of Cellular and Molecular Medicine, Medical Research Institute, Tokyo Medical and Dental University, Tokyo 1138510, Japan.
I am also a Young Science Ambassador to the Wonder of Science program. · Experience: Mater Medical Research Institute Limited · Education: The University of Queensland · Location: Greater Brisbane Area · 206 connections on LinkedIn. View Soi Cheng Law's profile on LinkedIn, a professional community of 1 billion members.
Mater Sci Eng C Mater Biol Appl. 2020 Jun;111:110750 ... Leninskiy pr. 4, 119049 Moscow, Russia; N. N. Blokhin National Medical Research Centre of Oncology of the Health Ministry of Russia, Kashirskoye sh. 24, 115478 ... Lomonosov Moscow State University, 119992 Moscow, Russia; All-Russia Research Institute of Agricultural Biotechnology, ...